Antibody-based therapy of human leukemia

Eneida Nemecek, Dana C. Matthews

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

During the past decades, monoclonal antibodies have been used as vehicles to deliver targeted therapy to sites of leukemic involvement. Anti-CD33 antibodies have been used alone - and more effectively, attached to chemotherapy agents or radioisotopes - to treat those with acute myeloid leukemia. Anti-CD45 antibodies have demonstrated an antileukemic effect when used either unconjugated or attached to radioactive iodine. Antibodies reactive with the myeloid antigen CD66 have been used to deliver targeted radiation to hematopoietic tissues in patients with advanced myeloid malignancies. Antibodies reactive with CD52 and CD20 antigens have been studied for the management of B-cell leukemia. This article reviews the most current clinical trials using monoclonal antibodies in the management of leukemia.

Original languageEnglish (US)
Pages (from-to)316-321
Number of pages6
JournalCurrent Opinion in Hematology
Volume9
Issue number4
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Anti-Idiotypic Antibodies
Leukemia
CD20 Antigens
Monoclonal Antibodies
B-Cell Leukemia
Antibodies
Acute Myeloid Leukemia
Radioisotopes
Iodine
Clinical Trials
Radiation
Drug Therapy
Therapeutics
Neoplasms
CD52 antigen
CD66 antigens

ASJC Scopus subject areas

  • Hematology

Cite this

Antibody-based therapy of human leukemia. / Nemecek, Eneida; Matthews, Dana C.

In: Current Opinion in Hematology, Vol. 9, No. 4, 2002, p. 316-321.

Research output: Contribution to journalArticle

Nemecek, Eneida ; Matthews, Dana C. / Antibody-based therapy of human leukemia. In: Current Opinion in Hematology. 2002 ; Vol. 9, No. 4. pp. 316-321.
@article{8e699d9a0dee45efa6cedf7af86ec58b,
title = "Antibody-based therapy of human leukemia",
abstract = "During the past decades, monoclonal antibodies have been used as vehicles to deliver targeted therapy to sites of leukemic involvement. Anti-CD33 antibodies have been used alone - and more effectively, attached to chemotherapy agents or radioisotopes - to treat those with acute myeloid leukemia. Anti-CD45 antibodies have demonstrated an antileukemic effect when used either unconjugated or attached to radioactive iodine. Antibodies reactive with the myeloid antigen CD66 have been used to deliver targeted radiation to hematopoietic tissues in patients with advanced myeloid malignancies. Antibodies reactive with CD52 and CD20 antigens have been studied for the management of B-cell leukemia. This article reviews the most current clinical trials using monoclonal antibodies in the management of leukemia.",
author = "Eneida Nemecek and Matthews, {Dana C.}",
year = "2002",
doi = "10.1097/00062752-200207000-00009",
language = "English (US)",
volume = "9",
pages = "316--321",
journal = "Current Opinion in Hematology",
issn = "1065-6251",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Antibody-based therapy of human leukemia

AU - Nemecek, Eneida

AU - Matthews, Dana C.

PY - 2002

Y1 - 2002

N2 - During the past decades, monoclonal antibodies have been used as vehicles to deliver targeted therapy to sites of leukemic involvement. Anti-CD33 antibodies have been used alone - and more effectively, attached to chemotherapy agents or radioisotopes - to treat those with acute myeloid leukemia. Anti-CD45 antibodies have demonstrated an antileukemic effect when used either unconjugated or attached to radioactive iodine. Antibodies reactive with the myeloid antigen CD66 have been used to deliver targeted radiation to hematopoietic tissues in patients with advanced myeloid malignancies. Antibodies reactive with CD52 and CD20 antigens have been studied for the management of B-cell leukemia. This article reviews the most current clinical trials using monoclonal antibodies in the management of leukemia.

AB - During the past decades, monoclonal antibodies have been used as vehicles to deliver targeted therapy to sites of leukemic involvement. Anti-CD33 antibodies have been used alone - and more effectively, attached to chemotherapy agents or radioisotopes - to treat those with acute myeloid leukemia. Anti-CD45 antibodies have demonstrated an antileukemic effect when used either unconjugated or attached to radioactive iodine. Antibodies reactive with the myeloid antigen CD66 have been used to deliver targeted radiation to hematopoietic tissues in patients with advanced myeloid malignancies. Antibodies reactive with CD52 and CD20 antigens have been studied for the management of B-cell leukemia. This article reviews the most current clinical trials using monoclonal antibodies in the management of leukemia.

UR - http://www.scopus.com/inward/record.url?scp=0036014981&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036014981&partnerID=8YFLogxK

U2 - 10.1097/00062752-200207000-00009

DO - 10.1097/00062752-200207000-00009

M3 - Article

C2 - 12042706

AN - SCOPUS:0036014981

VL - 9

SP - 316

EP - 321

JO - Current Opinion in Hematology

JF - Current Opinion in Hematology

SN - 1065-6251

IS - 4

ER -